Erin Boyer
Human Resources Officer bei UNIQURE N.V.
Profil
Erin Boyer is currently the Chief People & Culture Officer at uniQure NV since 2022.
Previously, she worked as the Head-Global Talent Strategy & Planning at Alnylam Pharmaceuticals, Inc., Chief People & Culture Officer at Epizyme, Inc., and Vice President-Human Resources at Obsidian Therapeutics, Inc. Ms. Boyer completed her undergraduate degree at Macalester College.
Aktive Positionen von Erin Boyer
| Unternehmen | Position | Beginn |
|---|---|---|
| UNIQURE N.V. | Human Resources Officer | 01.04.2022 |
Ehemalige bekannte Positionen von Erin Boyer
| Unternehmen | Position | Ende |
|---|---|---|
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Human Resources Officer | - |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| EPIZYME, INC. | Human Resources Officer | - |
Ausbildung von Erin Boyer
| Macalester College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| UNIQURE N.V. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
